Study Title: Phase III, Open-label, Multicenter, Randomized Control Trial in Patients with r/r Mantle Cell Lymphoma to Evaluate the Efficacy, Safety and Pharmacokinetics of Glofitamab, a CD20xCD3 Bispecific Antibody
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Brian Hess, at hessbr@musc.edu.Study Coordinator, Hana Baker, at bakerhan@musc.edu.Trial opened at the following institutions: Medical University of South Carolina